Correction: Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with ⁸⁹Zirconium oxine for PET imaging

Affiliations

• ¹ Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Office of Tissues and Advance Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
• ² Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ³ Wake Forest Institute of Regenerative Medicine, Winston Salem, NC, USA.
• ⁴ Iovance Biotherapeutics, San Carlos, CA, USA.
• ⁵ Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Office of Tissues and Advance Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA. [email protected].